Sino BiologicalInc Past Earnings Performance
Past criteria checks 1/6
Sino BiologicalInc's earnings have been declining at an average annual rate of -33.7%, while the Biotechs industry saw earnings growing at 3.1% annually. Revenues have been declining at an average rate of 32.4% per year. Sino BiologicalInc's return on equity is 3.2%, and it has net margins of 29.6%.
Key information
-33.7%
Earnings growth rate
-44.7%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | -32.4% |
| Return on equity | 3.2% |
| Net Margin | 29.6% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Sino BiologicalInc makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 660 | 195 | 306 | 91 |
| 31 Mar 24 | 642 | 220 | 304 | 88 |
| 31 Dec 23 | 646 | 260 | 291 | 87 |
| 30 Sep 23 | 620 | 232 | 263 | 80 |
| 30 Jun 23 | 568 | 246 | 250 | 73 |
| 31 Mar 23 | 556 | 272 | 223 | 73 |
| 01 Jan 23 | 575 | 303 | 208 | 60 |
| 30 Sep 22 | 583 | 440 | 193 | 47 |
| 30 Jun 22 | 630 | 470 | 173 | 45 |
| 31 Mar 22 | 685 | 502 | 157 | 43 |
| 01 Jan 22 | 965 | 720 | 146 | 40 |
| 30 Sep 21 | 1,341 | 933 | 139 | 40 |
| 30 Jun 21 | 1,736 | 1,236 | 143 | 33 |
| 31 Mar 21 | 1,942 | 1,396 | 162 | 28 |
| 31 Dec 20 | 1,596 | 1,128 | 151 | 25 |
| 31 Dec 19 | 181 | 36 | 88 | 23 |
| 31 Dec 18 | 139 | 36 | 57 | 22 |
| 31 Dec 17 | 101 | 13 | 41 | 21 |
Quality Earnings: 301047 has high quality earnings.
Growing Profit Margin: 301047's current net profit margins (29.6%) are lower than last year (43.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301047's earnings have declined by 33.7% per year over the past 5 years.
Accelerating Growth: 301047's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 301047 had negative earnings growth (-20.7%) over the past year, making it difficult to compare to the Biotechs industry average (10.1%).
Return on Equity
High ROE: 301047's Return on Equity (3.2%) is considered low.